Effects of atherectomy on major adverse limb events for femoropopliteal interventions: Vascular Quality Initiative registry
Catheterization and Cardiovascular Interventions · 2024
DOI: 10.1002/ccd.30912 ↗Kurz gefasst
Fachartikel in der Zeitschrift Catheterization and Cardiovascular Interventions, 2024. Verfasst von Valery S Effoe und 6 weiteren Autor:innen. Beteiligte Einrichtung: Aurora Cardiovascular and Thoracic Services, Aurora Sinai/Aurora St. Luke's Medical Centers, Advocate Aurora Health, Milwaukee, Wisconsin, USA. Hauptthemen laut MEDLINE: Peripheral Arterial Disease, Angioplasty, Balloon. Die Arbeit nennt 26 Literaturangaben.
Abstract (Originalsprache)
Background
Atherectomy use in treatment of femoropopliteal disease has significantly increased despite scant evidence of benefit to long‐term clinical outcomes.
Aims
We investigated the clinical benefits of atherectomy over standard treatment for femoropopliteal interventions.
Methods
Using data from the Society of Vascular Surgery's Vascular Quality Initiative (VQI) registry, we identified patients who underwent isolated femoropopliteal interventions for occlusive disease. We compared 13,423 patients treated with atherectomy with 47,371 receiving standard treatment; both groups were allowed definitive treatment with a drug‐coated balloon or stenting. The primary endpoint was major adverse limb events (MALEs), which is a composite of target vessel re‐occlusion, ipsilateral major amputation, and target vessel revascularization.
Results
Mean age was 69 ± 11 years, and patients were followed for a median of 30 months. Overall rates of complications were slightly higher in the atherectomy group than the standard treatment group (6.2% vs. 5.9%, p < 0.0001). In multivariable analysis, after adjusting for demographic and clinical covariates, atherectomy use was associated with a 13% reduction in risk of MALEs (adjusted odds ratio [aOR]: 0.87; 95% confidence interval [CI]: 0.77–0.98). Rates of major and minor amputations were significantly lower in the atherectomy group (3.2% vs. 4.6% and 3.3% vs. 4.3%, respectively, both p < 0.001), primarily driven by a significantly decreased risk of major amputations (aOR 0.69; 95% CI: 0.52–0.91). There were no differences in 30‐day mortality, primary patency, and target vessel revascularization between the atherectomy and standard treatment groups.
Conclusions
In adults undergoing femoropopliteal interventions, the use of atherectomy was associated with a reduction in MALEs compared with standard treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Aurora Cardiovascular and Thoracic Services, Aurora Sinai/Aurora St. Luke's Medical Centers, Advocate Aurora Health, Milwaukee, Wisconsin, USA.
- Division of Cardiovascular Medicine, University of Wisconsin School of Medicine and Public Health, Milwaukee Clinical Campus, Milwaukee, Wisconsin, USA.
ORCID-Profile: Valery S Effoe, Mark W Mewissen, Tanvir K Bajwa, Jayant Khitha, Louie Kostopoulos, Khawaja A Ammar, Tonga K Nfor
Zitieren
APA
Effoe, V. S., Mewissen, M. W., Bajwa, T. K., Khitha, J., Kostopoulos, L., Ammar, K. A., & Nfor, T. K. (2024). Effects of atherectomy on major adverse limb events for femoropopliteal interventions: Vascular Quality Initiative registry. Catheterization and Cardiovascular Interventions. https://doi.org/10.1002/ccd.30912
Vancouver
Effoe VS, Mewissen MW, Bajwa TK, Khitha J, Kostopoulos L, Ammar KA, et al. Effects of atherectomy on major adverse limb events for femoropopliteal interventions: Vascular Quality Initiative registry. Catheterization and Cardiovascular Interventions. 2024. doi:10.1002/ccd.30912
BibTeX
@article{Effoe2024,
author = {Effoe, Valery S and Mewissen, Mark W and Bajwa, Tanvir K and Khitha, Jayant and Kostopoulos, Louie and Ammar, Khawaja A and Nfor, Tonga K},
title = {Effects of atherectomy on major adverse limb events for femoropopliteal interventions: Vascular Quality Initiative registry},
journal = {Catheterization and Cardiovascular Interventions},
year = {2024},
doi = {10.1002/ccd.30912}
}
EUVIMED